Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational real world study to evaluate the malignancy risk in rheumatoid arthritis patients treated with Abatacept and that of Biologic Disease-modifying Antirheumatic Drug (bDMARD)

Trial Profile

An observational real world study to evaluate the malignancy risk in rheumatoid arthritis patients treated with Abatacept and that of Biologic Disease-modifying Antirheumatic Drug (bDMARD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs Abatacept (Primary) ; Adalimumab; Anakinra; Certolizumab pegol; Etanercept; Golimumab; Infliximab; Rituximab; Tocilizumab
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Dec 2018 Results published in the Rheumatology
    • 02 Jul 2017 New trial record
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top